SOURCE: Protea Biosciences

Protea Biosciences Group, Inc.

June 01, 2015 08:57 ET

Protea Announces Commercial Release of REDIchip™

New Chip Technology Provides Rapid and Sensitive Quantitation of Small Molecules

ST. LOUIS, MO--(Marketwired - June 01, 2015) - Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea") announced today that it is launching a new chip-based technology at the 63rd American Society of Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, held in St. Louis, MO. The nanopost array technology, called REDIchip™ (Resonance-Enhanced Desorption Ionization), was invented in the laboratory of Akos Vertes, PhD., Department of Chemistry, The George Washington University, and exclusively licensed to Protea.

"This week we are launching the REDIchip as a solution for researchers who desire to detect and quantify small molecules without the need of an interfering matrix using existing MALDI platforms. At ASMS, we have the opportunity to present several of the many applications of this new silicon chip, all made possible by the structured nanopost array design," stated Haddon Goodman, Imaging Program Manager at Protea. He continued, "The REDIchip manufacturing process uses established robust and reproducible methods of silicon chip production, enabling reliable and reproducible, matrix-free small molecule quantitation."

Several applications of Protea's REDIchip target plate are being presented at this week's ASMS conference, and the product is now available for commercial use. Select applications highlighting REDIchip workflows are being presented, including the metabolic profiling of biofluids (Tuesday, Poster 189), rapid quantitation of pharmaceutical drugs (Wednesday, Poster 159), and the quantitation of alkaloids in plant homogenates (Monday, Poster 246).

REDIchips are compatible with a variety of MALDI systems, and enable rapid and reproducible sample analysis of small molecules by laser desorption ionization.

For more information about the REDIchip, please visit our website at https://proteabio.com/products/REDIchip.

About Protea Biosciences Group, Inc.

Protea Biosciences Group, Inc. (OTCQB: PRGB) is a molecular information company providing innovative bioanalytical solutions to the pharmaceutical and life science industries. "Molecular information" refers to the generation and bioinformatic processing of very large data sets, obtained by applying the Company's technology to identify and characterize the proteins, metabolites, lipids and other biomolecules which are the byproducts of all living cells and life forms.

The Company is applying its technology to the development of next generation, "direct molecular imaging" technology and service capabilities that enable more rapid and comprehensive molecular profiling of human disease.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Protea and LAESI are registered trademarks of Protea Biosciences Group, Inc.

Contact Information